Updated Phase 1/2 data show that ozekibart plus FOLFIRI produced a 20% objective response rate and an 87% disease control ...
New preclinical data presented at AACR 2026 suggest opaganib may improve outcomes in two hard-to-treat cancers. In high-risk ...
Updated Phase 1 data presented at AACR 2026 suggest PLN-101095 plus pembrolizumab may help overcome secondary ICI resistance in advanced solid tumors. Among confirmed responders, average maximum tumor ...
The FDA has granted Breakthrough Device Designation to CatCHimera, the first MRD liquid biopsy in hepatocellular carcinoma to ...
The FDA has granted Priority Review to a supplemental application for perioperative enfortumab vedotin plus pembrolizumab in muscle-invasive bladder cancer, regardless of cisplatin eligibility. In the ...
TOBY’s urine-based MCED test received FDA Breakthrough Device Designation. This is the first urine-based MCED platform ...
At AACR 2026, Abbott presented data on Cancerguard, a multi-biomarker blood-based MCED test that combines methylation and ...
Researchers at MD Anderson identified DPY30 as a key biomarker and epigenetic regulator that enables pancreatic tumors to ...
Partner Therapeutics has submitted a supplemental Biologics License Application to the U.S. FDA for BIZENGRI, ...
Sarasota Memorial reported that 75% of lung cancers diagnosed through its early detection program were found at Stage I or II ...
Researchers from MD Anderson identified DHODH as a key metabolic driver of radiotherapy resistance in lung cancer. Radiation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results